These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

866 related articles for article (PubMed ID: 33578206)

  • 21. Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis.
    Kong L; Wang X; Chen H; Shi Z; Lang Y; Zhang Y; Zhou H
    Mult Scler Relat Disord; 2022 Dec; 68():104167. PubMed ID: 36170773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New onset or relapsing neuromyelitis optica temporally associated with SARS-CoV-2 infection and COVID-19 vaccination: a systematic review.
    Harel T; Gorman EF; Wallin MT
    Front Neurol; 2023; 14():1099758. PubMed ID: 37426444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing the consequences of COVID-19 vaccination between central nervous system (CNS) demyelinating diseases and other neurological disorders.
    Yazdan Panah M; Vaheb S; Mokary Y; Afshari-Safavi A; Shaygannejad A; Ebrahimi N; Shaygannejad V; Mirmosayyeb O
    Vaccine; 2024 Oct; 42(23):126061. PubMed ID: 38886142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders.
    Fragomeni MO; Bichuetti DB; Oliveira EML
    Mult Scler Relat Disord; 2018 Oct; 25():138-142. PubMed ID: 30075406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England.
    Garjani A; Patel S; Bharkhada D; Rashid W; Coles A; Law GR; Evangelou N
    Mult Scler Relat Disord; 2022 Jan; 57():103458. PubMed ID: 34896876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune responses following COVID-19 infection in multiple sclerosis patients using immunomodulatory therapy.
    Bilge N; Kesmez Can F; Yevgi R
    Acta Neurol Belg; 2023 Oct; 123(5):1885-1892. PubMed ID: 36331727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
    Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders.
    Fan M; Qiu W; Bu B; Xu Y; Yang H; Huang D; Lau AY; Guo J; Zhang MN; Zhang X; Yang CS; Chen J; Zheng P; Liu Q; Zhang C; Shi FD
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32503092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of disease-modifying drugs on the severity of  COVID-19 infection in multiple sclerosis patients.
    Rostami Mansoor S; Ghasemi-Kasman M
    J Med Virol; 2021 Mar; 93(3):1314-1319. PubMed ID: 33044760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Disease-Modifying Therapies on COVID-19 Vaccination Efficacy in Multiple Sclerosis Patients: A Comprehensive Review.
    Jamali E; Shapoori S; Farrokhi MR; Vakili S; Rostamzadeh D; Iravanpour F; Tavakoli Oliaee R; Jafarinia M
    Viral Immunol; 2023; 36(6):368-377. PubMed ID: 37276047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19 and the Pandemic-Related Aspects in Pediatric Demyelinating Disorders.
    Gombolay G; Hallman-Cooper J
    Semin Pediatr Neurol; 2023 Jul; 46():101055. PubMed ID: 37451752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case series and literature review of multiple sclerosis and COVID-19: Clinical characteristics, outcomes and a brief review of immunotherapies.
    Kataria S; Tandon M; Melnic V; Sriwastava S
    eNeurologicalSci; 2020 Dec; 21():100287. PubMed ID: 33163634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Outcome of COVID-19 in Pediatric-Onset Multiple Sclerosis Patients.
    Oncel I; Alici N; Solmaz I; Oge DD; Ozsurekci Y; Anlar B
    Pediatr Neurol; 2022 Sep; 134():7-10. PubMed ID: 35772229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccines: A systematic review.
    Mirmosayyeb O; Ghaffary EM; Vaheb S; Pourkazemi R; Shaygannejad V
    Rev Neurol (Paris); 2023 Apr; 179(4):265-281. PubMed ID: 36658048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
    Sormani MP; De Rossi N; Schiavetti I; Carmisciano L; Cordioli C; Moiola L; Radaelli M; Immovilli P; Capobianco M; Trojano M; Zaratin P; Tedeschi G; Comi G; Battaglia MA; Patti F; Salvetti M;
    Ann Neurol; 2021 Apr; 89(4):780-789. PubMed ID: 33480077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.
    Jakimovski D; Awan S; Eckert SP; Farooq O; Weinstock-Guttman B
    CNS Drugs; 2022 Jan; 36(1):45-59. PubMed ID: 34940954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of mental health, knowledge, and attitude of patients with multiple sclerosis and neuromyelitis optica spectrum disorder in response to 2019 novel coronavirus.
    Shaygannejad V; Afshari-Safavi A; Hatef B
    Neurol Sci; 2021 Jul; 42(7):2891-2901. PubMed ID: 33219424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post COVID-19 infection neuromyelitis optica spectrum disorder (NMOSD): A case report-based systematic review.
    Mirmosayyeb O; Ghaffary EM; Bagherieh S; Barzegar M; Dehghan MS; Shaygannejad V
    Mult Scler Relat Disord; 2022 Apr; 60():103697. PubMed ID: 35306242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis.
    Hada M; Mosholder AD; Leishear K; Perez-Vilar S
    Neurol Sci; 2022 Mar; 43(3):1557-1567. PubMed ID: 35006442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.
    Schiavetti I; Cordioli C; Stromillo ML; Teresa Ferrò M; Laroni A; Cocco E; Cola G; Pasquali L; Rilla MT; Signoriello E; Iodice R; Di Sapio A; Lanzillo R; Caleri F; Annovazzi P; Conte A; Liberatore G; Ruscica F; Docimo R; Bonavita S; Ulivelli M; Cavalla P; Patti F; Ferraro D; Clerico M; Immovilli P; Di Filippo M; Salvetti M; Sormani MP
    Mult Scler; 2022 Nov; 28(13):2106-2111. PubMed ID: 35735030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.